Telehealth Market & Telemedicine Market to Hit USD 180.86 Billion by 2030 with 11.5% CAGR
The Telehealth Market & Telemedicine market valued at US$ 83.62 Billion in 2023, is forecasted to grow at a robust CAGR of 11.5%, reaching US$ 94.14 Billion in 2024 and an impressive US$ 180.86 Billion by 2030. The telehealth and telemedicine market are experiencing significant growth primarily driven by the growing geriatric and medically underserved (especially rural) populations, the growing prevalence of chronic conditions, the benefits of telehealth & telemedicine given the current shortage of physicians and care personnel, and advancements in telecommunication technologies, and expansion of remote patient monitoring (RPM) systems. However, regulatory variations across regions, the rise in fraud and abuse within healthcare systems, and behavioural reluctance to adopt new technologies are expected to restrain the market growth during the forecast period.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=201868927
Browse in-depth TOC on " Telehealth Market & Telemedicine Market"
350 - Tables
50 - Figures
400 - Pages
Government initiatives to improve access to healthcare also play a vital role, often providing funding and resources to strengthen telehealth infrastructure, especially in underserved regions. Collaboration between technology firms and healthcare delivery organizations is a very important determinant that will have innovative solutions towards enhancing service delivery and engaging the patient to improved health outcomes. Together, these determinants drive growth in the market and change the face of the healthcare delivery scene to become responsive to patient needs and preferences.
By component, the software component is expected to capture the largest share of telehealth & telemedicine market during the forecast period. This would be due to the increasing demand for the digital health solution, which could be used for remote consultations, monitoring, and patient management. The software segment includes different tools and platforms, such as electronic health records (EHR), telemedicine applications, and patient management systems, which are important for providing virtual healthcare services. The product will increase productivity in the hands of healthcare providers through proper communication, real-time tracking of information, and inclusion into other service offerings. Moreover, the cloud-based platform and AI machine learning in application software also support their adoption by enriching the features of diagnosis, treatment plans, and predictive analytics. The healthcare systems that are increasingly adopting digital transformation will be dominated by software solutions in terms of scalability, flexibility, and improved patient outcomes.
By Age group, adults segment is dominated the telehealth & telemedicine market. This is due to the steadily rising prevalence rate of chronic diseases and the growing desire for healthcare care among adults. Adults, especially those above age 40, normally require regular and continued monitoring management of conditions for diabetes, high blood pressure as well as cardiovascular-related diseases, which telehealth can be very useful. Telemedicine is easy and convenient for adults to access healthcare services without the need for frequent in-person visits, which is very helpful for people with mobility issues, busy schedules, or limited access to healthcare facilities. Moreover, adults are more likely to embrace technology and use digital health solutions for managing their health, thus contributing to the dominance of the segment in the telehealth and telemedicine market.
The major players in the telehealth & telemedicine market with a significant global presence are Koninklijke Philips N.V. (Netherlands), Medtronic (Ireland), GE Healthcare (US), Epic Systems Corporation (US), Oracle (US), Doximity, Inc. (US), Teladoc Health, Inc. (US), American Well (US), Siemens Healthineers AG (Germany), Cisco Systems Inc. (US), Included Health, Inc. (Doctor on Demand, Inc.) (US), AMC Health (US), TeleSpecialists (US), Walgreen Co. (US), Caregility (US), CVS Health (US), EverNorth Health, Inc. (US), Elation (US), Iron Bow Healthcare Solutions (US), and Zoom Communications, Inc. (US), Timedoc Health (US), Cerebral Inc. (US), Kindbody (US), Transcarent (US), and Caresimple, Inc. (US). The market players have adopted strategies such as acquisitions, collaborations, partnerships, mergers, product/service launches & enhancements, and approvals to strengthen their position in the telehealth & telemedicine market. The product and technology innovations have helped the market players expand globally by providing telehealth & telemedicine solutions.
These players not only have a comprehensive and diverse product portfolio but also a strong geographic presence. With the increasing adoption of telehealth and telemedicine in various healthcare applications, these players can focus on developing innovative virtual care platforms and adaptive trial design advanced remote patient monitoring solutions, and integrated telemedicine services.
These market players offer a diverse range of products and services worldwide. They rely on technological advancements to develop innovative products and services and increase their global footprint. Increasing focus on acquisitions, collaborations, partnerships, mergers, product/service launches and enhancements, and approvals, facilitate the market players to expand their global reach and develop advanced telehealth & telemedicine solutions to sustain their market positions.
Koninklijke Philips N.V
Koninkliike Philips N.V. is a diversified technology-based company in the healthcare and consumer lifestyle markets. It is one of the leading companies in the healthcare sector with a strong presence in cardiac care, acute care, and home healthcare. The company operates through four segments: Personal Health, Diagnosis & Treatment, Connected Care, and Others. The telehealth and telemedicine services fall under the connected care segment. The connected care segment consists of following business's monitoring, sleep & respiratory care and enterprise informatics. The telehealth solutions are used by providers and patients. The company operates in North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In November 2024, Philips has received FDA approval for remote scanning and protocol management features in its Radiology Operations Command Centre (ROCC), allowing radiologists to assist with scans remotely. In January 2023, Philips and Masimo expanded their partnership to enhance telehealth by integrating the Masimo W1 health-tracking watch with Philips' monitoring systems for better patient care at home.
Medtronic
Medtronic is one of the largest medical technology, services, and solutions companies globally. The company operates through four principal segments, namely, Cardiovascular, Diabetes, Medical Surgical, and Neuroscience. The company extends telehealth solutions across all four segments. Within the Cardiac and Vascular segment, it offers products and services to diagnose, treat, and manage cardiac rhythm disorders and cardiovascular diseases. Medtronic's portfolio encompasses remote monitoring platforms and patient-cantered software through its products and Medtronic Care Management Services. The telehealth solutions offered by the company cover glucose management and cardiac condition management. Medtronic's telehealth device offerings include Bluetooth-enabled and direct-connect peripherals. These devices comprise weight scales, glucometers, blood pressure monitors, pulse oximeters, pedometers, and activity trackers. Medtronic serves its customers in ~160 countries worldwide. The company operates in North America, Latin America, Europe, Asia Pacific, Middle East and Africa and Russia.
Epic Systems Corporation
Epic Systems is a software development, installation, and support company that also provides consulting services. The company establishes healthcare management software that combines financial and clinical information from inpatient, ambulatory, and payer technology systems. The company's core competency is to provide EHR software solutions. Epic Systems Corporation is integrating Al into telehealth and telemedicine through strategic partnerships with Microsoft and generative Al technologies. Epic aims to improve productivity and patient care in virtual healthcare settings by combining its EHR solutions with Microsoft's Azure OpenAl Service. This encompasses improving workflows, enabling generative Al to compose message responses, and supporting natural language queries. Epic's Al efforts also focus on enhancing self-service reporting tools, maintaining financial integrity, and improving clinical outcomes, all of which will enhance global telehealth and telemedicine systems. It operates its offices in the US, UK, Canada, Denmark, the Netherlands, Norway, Saudi Arabia, the UAE, Finland, Ireland, Australia, Singapore, and Switzerland.
For more information, Inquire Now!
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
2 days ago
- Globe and Mail
Saskatchewan Tech Company Launches CabinPulse Cares Program, Donating Remote Monitoring Systems to Community Organizations Across Canada
"The program addresses a critical need for community organizations operating on limited budgets while protecting valuable community assets from Canada's extreme weather conditions." Toccata, Inc., the Saskatchewan-based technology company behind CabinPulse remote monitoring systems, today announced the official launch of CabinPulse Cares, a charitable initiative providing free monitoring devices and service to qualifying non-profit organizations, community centres, and charitable institutions across Canada. Toccata, Inc., the Saskatchewan-based technology company behind CabinPulse remote monitoring systems, today announced the official launch of CabinPulse Cares, a charitable initiative providing free monitoring devices and service to qualifying non-profit organizations, community centres, and charitable institutions across Canada. The program addresses a critical need for community organizations operating on limited budgets while protecting valuable community assets from Canada's extreme weather conditions. From prairie blizzards to coastal storms, Canadian communities face unique environmental challenges that can cause costly damage through temperature extremes, power outages, and other environmental threats. This need is particularly acute in rural communities, where strong community spaces often serve as vital gathering points but may lack reliable internet infrastructure. " We believe every community space deserves protection," said Noah Little, a representative from Toccata, Inc. " Many of the organizations that serve as the backbone of our communities – churches, volunteer fire departments, food banks, and community centres – operate on limited budgets while providing essential services. Through CabinPulse Cares, we're ensuring these vital spaces have the same level of protection as any commercial property." Program Details Qualifying organizations receive a complete protection package at no charge including: One CabinPulse monitoring device (valued at $199 CAD) Three years of monitoring service with unlimited alerts and data (valued at $360 CAD) Free setup support and dedicated assistance The combined value of over $500 represents a significant investment in property protection. The device monitors temperature, humidity, power outages, and air quality without requiring any existing wireless infrastructure like WiFi, making it perfect for rural community buildings, remote locations, or facilities with limited internet connectivity. The cellular-connected device can provide instant alerts via text and email to multiple people when issues are detected, helping prevent damage from frozen pipes, power failures, or environmental hazards – especially critical during Canada's harsh winters. Eligible Organizations CabinPulse Cares is available exclusively to Canadian organizations including: Places of worship Volunteer fire departments and emergency services Community centres and senior centres Food banks and community kitchens Shelters and transitional housing Youth organizations and social service providers Supporting Canadian Communities The program reflects Toccata's commitment to giving back to the communities that make Canada strong. From bustling urban centres to remote rural towns, Canadian communities are defined by their resilience and the vital spaces where people gather. By focusing on organizations that provide essential services, CabinPulse Cares helps ensure that community spaces remain operational and protected year-round, particularly during harsh Canadian winters when environmental monitoring becomes critical for preventing costly damage. The system's ability to operate without existing wireless infrastructure makes it uniquely suited for rural and remote community buildings that form the heart of Canada's smaller communities. Application Process Organizations are invited to apply online at Applications are reviewed monthly, with recipients selected based on community impact and demonstrated need. The streamlined application asks organizations to describe their mission, community impact, and how remote monitoring would benefit their operations. About CabinPulse CabinPulse is a cellular-connected monitoring system designed and assembled in Saskatoon, Saskatchewan. The device provides reliable remote monitoring for temperature, humidity, power outages, and air quality without requiring WiFi or any existing wireless infrastructure, and features simple installation. CabinPulse serves property owners, managers, and organizations who need dependable monitoring for remote or unattended locations. About Toccata, Inc. Founded in 2022, Toccata, Inc. is a Saskatchewan-based technology company focused on creating reliable, user-friendly solutions for real-world problems. The company remains committed to its mission of making remote property monitoring simple, reliable, and affordable for everyone. For more information about CabinPulse Cares or to apply for the program, visit
Global News
2 days ago
- Global News
West Nile virus to spread to remote areas of Quebec due to climate change, study says
Quebec public health officials are warning of another potential consequence of climate change. A recent study by the Public Health Institute suggests warmer temperatures could lead to a surge in West Nile virus cases and that it could spread to more remote regions of the province for the first time. Get weekly health news Receive the latest medical news and health information delivered to you every Sunday. Sign up for weekly health newsletter Sign Up By providing your email address, you have read and agree to Global News' Terms and Conditions and Privacy Policy The virus is often found in Quebec's larger city centres, especially around Montreal. But by 2080, the virus could migrate, going as for as Gaspé and even north to the Abitibi region. As Global's Franca Mignacca reports, warming weather coupled with increased precipitation is expected to increase its spread, as well as other mosquito and tick-born diseases. For the full story, watch the video above.
Globe and Mail
2 days ago
- Globe and Mail
EGFR + NSCLC Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Therapeutics Segment
DelveInsight's, 'EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Pipeline Insight, 2025' report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) pipeline landscape. It covers the EGFR + NSCLC pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore our latest breakthroughs in EGFR + NSCLC research. Learn more about our innovative pipeline today! @ EGFR + NSCLC Pipeline Outlook Key Takeaways from the EGFR + NSCLC Pipeline Report In July 2025, ETOP IBCSG Partners Foundation announced a primary objective of the trial is to assess the efficacy of amivantamab and bevacizumab added to continued treatment with the third-generation EGFR-TKI lazertinib, in patients with EGFR-mutant advanced NSCLC, who have been previously treated with a third-generation EGFR-TKI in order to provide data on treatment effect and sample size required for a future phase III trial. In June 2025, BlossomHill Therapeutics conducted a study in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) and/or human epidermal growth factor receptor (HER2) mutations. The study drug, BH-30643 capsules, will be self-administered by mouth twice daily in 21-day cycles. In June 2025, Merck Sharp & Dohme LLC organized a study is to evaluate sacituzumab tirumotecan versus pemetrexed in combination with carboplatin for the treatment of epidermal growth factor receptor (EGFR)-mutated advanced non-squamous non-small cell lung cancer (NSCLC). Participants in this study have NSCLC that has continued to progress on prior treatment with EGFR tyrosine kinase inhibitors (TKIs). DelveInsight's EGFR + NSCLC pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for EGFR + NSCLC treatment. The leading EGFR + NSCLC Companies such as Cullinan Oncology, Betta Pharmaceuticals, G1 Therapeutics, Janux Therapeutics, Daiichi Sankyo Company, Suzhou Puhe Pharmaceutical Technology, Genor Biopharma, J Ints Bio, Avistone Pharmaceuticals, Mythic Therapeutics and others. Promising EGFR+NSCLC Pipeline Therapies such as IN10018, Furmonertinib, Oral S-1 + Oral Osimertinib, YH25448, JS111 capsules (AP-L1898), Osimertinib, Gefitinib, RC108, Sunvozertinib, and others. Stay informed about the cutting-edge advancements in EGFR + NSCLC treatments. Download for updates and be a part of the revolution in cancer care @ EGFR + NSCLC Clinical Trials Assessment EGFR + NSCLC Emerging Drugs Profile CLN-081 is a novel irreversible Epidermal Growth Factor Receptor (EFGR) inhibitor. It is administered through oral route, and is developed by Cullinan Oncology. The drug is being developed in association with Taiho Pharmaceuticals. The drug is currently being investigated in the Phase III stage of development for the treatment of EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC). BPI-361175: Betta Pharmaceuticals BPI-361175 is a novel, oral, highly potent and selective 4th generation EGFR inhibitor developed by Betta Pharmaceutical Co., Ltd. The new chemical entity targets EGFR C797S mutation and other EGFR related mutations that are resistant to 3rd generation EGFR TKI in non-small cell lung cancer (NSCLC) and other solid tumors. It shows excellent inhibitory effect and selectivity in vitro assay and exhibits significant anti-tumor activity in a variety of xenograft models harboring EGFR C797S or other related mutations. The IND application of BPI-361175 has been approved by NMPA. Currently, the drug is the Phase I/II stage of its development for the treatment of Non-small Cell Lung Cancer. G1T38: G1 Therapeutics G1T38 is an investigational, oral CDK4/6 inhibitor designed to be used along with other targeted therapies for various oncology indications. G1 Therapeutics has entered a clinical trial collaboration to assess its G1T38 in combination with AstraZeneca's Tagrisso (osimertinib) in a Phase Ib/II clinical trial to treat patients suffering from EGFR mutation-positive non-small cell lung cancer (NSCLC). Currently, the drug is being evaluated in the Phase I/II stage in combination with osimertinib in patients with EGFR mutation-positive metastatic non-small cell lung cancer. JANX008: Janux Therapeutics JANX008, is a TRACTr that targets Epidermal Growth Factor Receptor (EGFR), and is being developed by Janux Therapeutics for the treatment of various solid tumors including non-small cell lung cancer. According to preclinical studies, JANX008 showed potent cleavage dependent anti-tumor activity, with limited toxicities in healthy tissues or CRS. JANX008, is currently being evaluated in phase I clinical trial for the treatment of various solid tumors. The EGFR + NSCLC Pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of EGFR + NSCLC with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for EGFR + NSCLC Treatment. EGFR + NSCLC Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. EGFR + NSCLC Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the EGFR + NSCLC market. Learn more about EGFR + NSCLC Drugs opportunities in our groundbreaking EGFR + NSCLC research and development projects @ EGFR + NSCLC Unmet Needs EGFR + NSCLC Companies Cullinan Oncology, Betta Pharmaceuticals, G1 Therapeutics, Janux Therapeutics, Daiichi Sankyo Company, Suzhou Puhe Pharmaceutical Technology, Genor Biopharma, J Ints Bio, Avistone Pharmaceuticals, Mythic Therapeutics and others. EGFR Non-Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Intravenous Subcutaneous Oral Intramuscular EGFR + NSCLC Products have been categorized under various Molecule types such as Monoclonal antibody Small molecule Peptide Discover the latest advancements in EGFR + NSCLC treatment by visiting our website. Stay informed about how we're transforming the future of oncology @ EGFR + NSCLC Market Drivers and Barriers, and Future Perspectives Scope of the EGFR + NSCLC Pipeline Report Coverage- Global EGFR + NSCLC Companies- Cullinan Oncology, Betta Pharmaceuticals, G1 Therapeutics, Janux Therapeutics, Daiichi Sankyo Company, Suzhou Puhe Pharmaceutical Technology, Genor Biopharma, J Ints Bio, Avistone Pharmaceuticals, Mythic Therapeutics and others. EGFR+NSCLC Pipeline Therapies- IN10018, Furmonertinib, Oral S-1 + Oral Osimertinib, YH25448, JS111 capsules (AP-L1898), Osimertinib, Gefitinib, RC108, Sunvozertinib, and others. EGFR + NSCLC Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination EGFR + NSCLC Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III For a detailed overview of our latest research findings and future plans, read the full details of EGFR + NSCLC Pipeline on our website @ EGFR + NSCLC Emerging Drugs and Companies Table of Contents Introduction Executive Summary EGFR Non-Small Cell Lung Cancer: Overview Pipeline Therapeutics Therapeutic Assessment EGFR Non-Small Cell Lung Cancer – DelveInsight's Analytical Perspective Late Stage Products (Phase III) CLN-081: Cullinan Oncology Drug profiles in the detailed report….. Mid Stage Products (Phase II) Drug Name: Company Name Drug profiles in the detailed report….. Early Stage Products (Phase I/II) BPI-361175: Betta Pharmaceuticals Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug Name: Company Name Drug profiles in the detailed report….. Inactive Products EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Key Companies EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Key Products EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC)- Unmet Needs EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC)- Market Drivers and Barriers EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC)- Future Perspectives and Conclusion EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Analyst Views EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
